Melvin Churchill

3.8k total citations · 1 hit paper
21 papers, 2.1k citations indexed

About

Melvin Churchill is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Melvin Churchill has authored 21 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 9 papers in Genetics and 8 papers in Hematology. Recurrent topics in Melvin Churchill's work include Rheumatoid Arthritis Research and Therapies (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Melvin Churchill is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Melvin Churchill collaborates with scholars based in United States, United Kingdom and Switzerland. Melvin Churchill's co-authors include Karl N. Miller, Katherine A. Owen, Paul Beckett, Alan H. Drummond, Matthew Mangan, William C. Thomas, Sachin Patel, John M. Clements, A. J. H. Gearing and Robert J.C. Gilbert and has published in prestigious journals such as Nature, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

Melvin Churchill

20 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Processing of tumour necrosis factor-α precursor by metalloproteinases

1994 1.0k citations A. J. H. Gearing, Paul Beckett et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melvin Churchill United States	12	889	569	521	468	356	21	2.1k
Bernard Grillet Netherlands	21	853 1.0×	348 0.6×	463 0.9×	209 0.4×	336 0.9×	42	1.6k
Hans P. Kiener Austria	29	803 0.9×	209 0.4×	700 1.3×	153 0.3×	336 0.9×	51	2.2k
Sherry Thornton United States	26	370 0.4×	646 1.1×	692 1.3×	184 0.4×	213 0.6×	67	2.0k
Gisela Orozco United Kingdom	31	858 1.0×	248 0.4×	1.3k 2.5×	239 0.5×	264 0.7×	75	2.6k
Lisa G. M. van Baarsen Netherlands	31	1.5k 1.7×	295 0.5×	1.4k 2.6×	186 0.4×	615 1.7×	76	3.1k
Yojiro Arinobu Japan	26	448 0.5×	516 0.9×	1.5k 2.9×	136 0.3×	281 0.8×	77	2.8k
Martine Chabaud France	10	989 1.1×	413 0.7×	1.6k 3.1×	215 0.5×	664 1.9×	12	2.6k
Erika Darrah United States	23	1.1k 1.3×	172 0.3×	871 1.7×	188 0.4×	335 0.9×	62	2.5k
Daisuke Goto Japan	26	663 0.7×	180 0.3×	945 1.8×	128 0.3×	302 0.8×	105	2.0k
Peggy Jacques Belgium	26	1.4k 1.6×	677 1.2×	1.4k 2.7×	306 0.7×	237 0.7×	54	2.9k

Countries citing papers authored by Melvin Churchill

Since Specialization

Citations

This map shows the geographic impact of Melvin Churchill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Churchill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Churchill more than expected).

Fields of papers citing papers by Melvin Churchill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Churchill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Churchill. The network helps show where Melvin Churchill may publish in the future.

Co-authorship network of co-authors of Melvin Churchill

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Churchill. A scholar is included among the top collaborators of Melvin Churchill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Churchill. Melvin Churchill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dumortier, Thomas, Guillermo J. Valenzuela, Melvin Churchill, et al.. (2025). Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis. Clinical Pharmacology & Therapeutics. 118(2). 480–488.

Kivitz, Alan, Melvin Churchill, Atul Singhal, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. 77(2). 171–179. 1 indexed citations

Nguyen, Tien N., Melvin Churchill, Robert M. Levin, et al.. (2022). Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. The Journal of Rheumatology. 49(8). 894–902. 11 indexed citations

Neogi, Tuhina, David J. Hunter, Melvin Churchill, et al.. (2022). Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Research & Therapy. 24(1). 78–78. 17 indexed citations

Curtis, Jeffrey R., Melvin Churchill, Alan Kivitz, et al.. (2015). A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. Arthritis & Rheumatology. 67(12). 3104–3112. 19 indexed citations

Emery, Paul, Roy Fleischmann, Ingrid Strusberg, et al.. (2015). Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial. Arthritis Care & Research. 68(6). 744–752. 34 indexed citations

Rahman, Proton, Vibeke Strand, Iain B. McInnes, et al.. (2015). THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial. Annals of the Rheumatic Diseases. 74. 356–356. 3 indexed citations

Bar‐Or, David, Kristin Salottolo, Matthew J. Phillips, et al.. (2014). A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee. PLoS ONE. 9(2). e87910–e87910. 41 indexed citations

Emery, Paul, Roy Fleischmann, Ingrid Strusberg, et al.. (2014). 97. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Methotrexate-NaïVe Patients with Rheumatoid Arthritis. Lara D. Veeken. 53(suppl_1). i93–i93. 3 indexed citations

10.

Curtis, Jeffrey R., Melvin Churchill, Alan Kivitz, et al.. (2014). FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study. Annals of the Rheumatic Diseases. 73. 382–382. 2 indexed citations

11.

Emery, Paul, Roy Fleischmann, Mittie K. Doyle, et al.. (2013). Golimumab, a Human Anti–Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study. Arthritis Care & Research. 65(11). 1732–1742. 34 indexed citations

12.

Martinꝉ, Roland, Melvin Churchill, Luis Felipe Flores-Suárez, et al.. (2013). A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Research & Therapy. 15(5). R164–R164. 91 indexed citations

13.

Emery, Paul, Roy Fleischmann, Larry W. Moreland, et al.. (2009). Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. Arthritis & Rheumatism. 60(8). 2272–2283. 335 indexed citations

14.

Fleischmann, R, Patrick Durez, P. Emery, et al.. (2008). Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study. DIAL (Catholic University of Leuven). 58(9). 4 indexed citations

15.

O’Dell, James R., Robert D. Leff, Claire E. Haire, et al.. (2002). Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 46(5). 1164–1170. 221 indexed citations

16.

Weaver, A., et al.. (1999). Improved Gastrointestinal Tolerance and Patient Preference of Enteric-Coated Sulfasalazine Versus Uncoated Sulfasalazine Tablets in Patients with Rheumatoid Arthritis. JCR Journal of Clinical Rheumatology. 5(4). 193–200. 7 indexed citations

17.

O’Dell, James R., Claire E. Haire, William Palmer, et al.. (1999). Treatment of early seropositive rheumatoid arthritis with minocycline: Four-year followup of a double-blind, placebo-controlled trial. Arthritis & Rheumatism. 42(8). 1691–1695. 84 indexed citations

18.

O’Dell, James R., Claire E. Haire, William Palmer, et al.. (1997). Treatment of early Rheumatoid Arthritis with minocycline or placebo. Results of a Randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 40(5). 842–848. 130 indexed citations

19.

Gearing, A. J. H., Paul Beckett, Marika Christodoulou, et al.. (1994). Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature. 370(6490). 555–557. 1021 indexed citations breakdown →

20.

Kirkham, Bruce, et al.. (1991). Anterolateral rupture of popliteal cysts in rheumatoid arthritis.. Annals of the Rheumatic Diseases. 50(3). 187–188. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact